These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159 [TBL] [Abstract][Full Text] [Related]
43. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer. Lo A; McSharry M; Berger AH BMC Cancer; 2022 Dec; 22(1):1315. PubMed ID: 36522653 [TBL] [Abstract][Full Text] [Related]
44. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress. Hong BJ; Park WY; Kim HR; Moon JW; Lee HY; Park JH; Kim SK; Oh Y; Roe JS; Kim MY Cancer Res; 2019 Nov; 79(22):5849-5859. PubMed ID: 31506334 [TBL] [Abstract][Full Text] [Related]
45. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Xue JY; Zhao Y; Aronowitz J; Mai TT; Vides A; Qeriqi B; Kim D; Li C; de Stanchina E; Mazutis L; Risso D; Lito P Nature; 2020 Jan; 577(7790):421-425. PubMed ID: 31915379 [TBL] [Abstract][Full Text] [Related]
46. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979 [TBL] [Abstract][Full Text] [Related]
47. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157 [TBL] [Abstract][Full Text] [Related]
48. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110 [TBL] [Abstract][Full Text] [Related]
49. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279 [TBL] [Abstract][Full Text] [Related]
50. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449 [TBL] [Abstract][Full Text] [Related]
51. Modulation of Mutant Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919 [TBL] [Abstract][Full Text] [Related]
53. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987 [TBL] [Abstract][Full Text] [Related]
54. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720 [TBL] [Abstract][Full Text] [Related]
55. Characterization of Kim S; Kim J; Jung Y; Jun Y; Jung Y; Lee HY; Keum J; Park BJ; Lee J; Kim J; Lee S; Kim J Mol Cells; 2020 Jul; 43(7):619-631. PubMed ID: 32638704 [TBL] [Abstract][Full Text] [Related]
56. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161 [TBL] [Abstract][Full Text] [Related]
57. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid. Frankel D; Nanni-Metellus I; Robaglia-Schlupp A; Tomasini P; Guinde J; Barlesi F; Astoul P; Ouafik L; Amatore F; Secq V; Kaspi E; Roll P Clin Chem Lab Med; 2018 Apr; 56(5):851-856. PubMed ID: 29306909 [TBL] [Abstract][Full Text] [Related]
58. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells. Komatsu N; Fujita Y; Matsuda M; Aoki K Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330 [TBL] [Abstract][Full Text] [Related]
59. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status. Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746 [TBL] [Abstract][Full Text] [Related]
60. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. Bauer AK; Umer M; Richardson VL; Cumpian AM; Harder AQ; Khosravi N; Azzegagh Z; Hara NM; Ehre C; Mohebnasab M; Caetano MS; Merrick DT; van Bokhoven A; Wistuba II; Kadara H; Dickey BF; Velmurugan K; Mann PR; Lu X; Barón AE; Evans CM; Moghaddam SJ JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089720 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]